Provider Briefing: Blisovi Fe 1/20 Availability in 2026

Oral contraceptive availability has become an increasingly common challenge in clinical practice. Patients on Blisovi 21 Fe 1/20 28 Day Pack (Norethindrone Acetate 1 mg/Ethinyl Estradiol 0.02 mg with Ferrous Fumarate) are among those affected, with many reporting difficulty filling prescriptions at retail pharmacies.

This briefing provides an overview of the current availability landscape, prescribing implications, therapeutic alternatives, and tools to help your patients maintain uninterrupted access to contraception.

Timeline: How We Got Here

The availability issues with Blisovi Fe 1/20 and related Norethindrone Acetate/Ethinyl Estradiol products have developed gradually:

• 2022-2023: Post-pandemic supply chain recovery was uneven across pharmaceutical manufacturers. Raw material sourcing for hormone-based APIs (active pharmaceutical ingredients) remained constrained.
• 2023-2024: Several generic oral contraceptive manufacturers experienced production slowdowns. Industry consolidation reduced the number of active producers for low-dose combination OCs.
• 2024-2025: Insurance formulary shifts drove demand surges for specific generics, including Blisovi Fe 1/20. Regional stock-outs became more frequent at chain pharmacies.
• 2026 (current): Blisovi Fe 1/20 is not listed on the FDA Drug Shortages database, but patient-reported availability issues persist. Supply is inconsistent across pharmacy chains and regions.

Prescribing Implications

The intermittent availability of Blisovi Fe 1/20 has several clinical considerations for prescribers:

Continuity of Contraception

Gaps in oral contraceptive use increase the risk of unintended pregnancy. Patients who cannot fill their Blisovi Fe 1/20 prescription may go days or weeks without contraception unless proactive steps are taken. This is particularly concerning for patients who may not feel comfortable initiating a conversation with their provider about supply issues.

Generic Substitution Awareness

Many patients may not realize that their pharmacist can substitute an A-rated generic equivalent without a new prescription. Proactively educating patients about therapeutic equivalents — and documenting "may substitute" or "dispense as written" preferences appropriately — can reduce unnecessary gaps.

Side Effect Variability Between Generics

While all A-rated generics of Loestrin Fe 1/20 contain identical active ingredients, patients occasionally report differences in tolerability due to variations in inactive ingredients (binders, fillers, dyes). If a patient has a strong preference for a specific manufacturer, note this in their chart while emphasizing that any equivalent generic is preferable to a gap in contraception.

Current Availability Picture

Based on pharmacy-level data and patient reports in early 2026:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Stock levels are inconsistent. Blisovi Fe 1/20 may be available at one location but not another within the same metropolitan area.
• Independent pharmacies: Generally more reliable, as they often work with multiple wholesalers and maintain more flexible ordering.
• Mail-order pharmacies: Tend to have better availability for 90-day supplies.
• Hospital/health system pharmacies: May carry limited OC inventory but can sometimes access stock through health system distribution channels.

Providers can direct patients to Medfinder for Providers to check real-time pharmacy availability in their area.

Cost and Access Considerations

Understanding the cost landscape helps when counseling patients:

• Cash price: $34 to $75 per 28-tablet pack
• Discount card pricing: $13 to $20 per pack through GoodRx, SingleCare, or similar programs
• Insurance coverage: Most commercial plans and Medicaid cover generic OCs at $0 copay under the ACA contraceptive coverage mandate
• Uninsured patients: Discount cards, 340B pharmacies, and Title X family planning clinics offer substantially reduced pricing

No manufacturer savings program exists for Blisovi Fe 1/20 from Lupin Pharmaceuticals. Patient assistance is primarily through third-party discount cards and safety-net programs.

Therapeutic Alternatives

When Blisovi Fe 1/20 is unavailable, the following A-rated generic equivalents can be substituted directly:

• Junel Fe 1/20 (Teva) — Same formulation, widely available
• Microgestin Fe 1/20 (Mayne Pharma) — One of the most dispensed OCs nationally
• Larin Fe 1/20 (Northstar Rx) — Same active ingredients
• Aurovela Fe 1/20 (Aurobindo) — Another equivalent generic option

All contain Norethindrone Acetate 1 mg/Ethinyl Estradiol 0.02 mg with Ferrous Fumarate placebo tablets.

For patients who may benefit from a formulation change:

• Blisovi 24 Fe / Loestrin 24 Fe generics: 24 active pills + 4 placebo pills — shorter hormone-free interval, potentially better cycle control
• Lo Loestrin Fe: Lower estrogen (10 mcg EE) — brand-only, higher cost, but may be appropriate for patients sensitive to estrogen-related side effects
• Blisovi Fe 1.5/30: Higher dose option (1.5 mg NETA/0.03 mg EE) — may provide better cycle control for patients with breakthrough bleeding

Tools and Resources for Your Practice

Several tools can help streamline the process of connecting patients with available contraception:

• Medfinder for Providers: Real-time pharmacy stock search — share with patients or use at the point of care
• Pharmacy benefit manager (PBM) portals: Check formulary status and prior authorization requirements for alternatives
• Electronic prescribing systems: Many EHR systems now display pharmacy inventory data — check if your system supports this feature
• State prescription drug monitoring programs: While primarily for controlled substances, some states are expanding monitoring to include supply data for high-demand medications

Looking Ahead

The oral contraceptive supply landscape is unlikely to change dramatically in the near term. Manufacturing consolidation, thin margins on generic hormonal products, and persistent supply chain constraints will continue to create periodic availability challenges.

Proactive strategies — including prescribing with generic substitution flexibility, educating patients about equivalents, and leveraging pharmacy stock tools — can help minimize disruptions to patient care.

Final Thoughts

The Blisovi Fe 1/20 availability situation exemplifies a broader trend in generic medication access. While not an FDA-designated shortage, the real-world impact on patients is significant. By staying informed about the supply landscape and equipping your patients with tools like Medfinder, you can help ensure continuity of contraceptive care even during supply disruptions.

For additional clinical resources, see our companion articles on helping patients find Blisovi Fe 1/20 in stock and helping patients save money on their prescription.